BioCentury | May 16, 2011
Company News

Biocoll GmbH, Genfit, University of Freiburg deal

...began in 2007 and resulted in the successful identification of potential compounds for the receptor. Biocoll...
BioCentury | May 5, 1997
Company News

Biocoll board of directors update

Biocoll Medical Corp. (VSE:BLM), Vancouver, B.C. Business: Musculoskeletal Appointed: Ian Lennox, president and CEO of Drug Royalty Corp.; Clifford Nordal, president and CEO of Queen Elizabeth Hospital and assistant professor, faculty of medicine, University of...
BioCentury | Jan 27, 1997
Company News

Biocoll, Osteopharm Ltd. deal

...acquisition and the financing, BLM has 30.9 million shares outstanding on a fully diluted basis. Biocoll Medical Corp....
Items per page:
1 - 3 of 3
BioCentury | May 16, 2011
Company News

Biocoll GmbH, Genfit, University of Freiburg deal

...began in 2007 and resulted in the successful identification of potential compounds for the receptor. Biocoll...
BioCentury | May 5, 1997
Company News

Biocoll board of directors update

Biocoll Medical Corp. (VSE:BLM), Vancouver, B.C. Business: Musculoskeletal Appointed: Ian Lennox, president and CEO of Drug Royalty Corp.; Clifford Nordal, president and CEO of Queen Elizabeth Hospital and assistant professor, faculty of medicine, University of...
BioCentury | Jan 27, 1997
Company News

Biocoll, Osteopharm Ltd. deal

...acquisition and the financing, BLM has 30.9 million shares outstanding on a fully diluted basis. Biocoll Medical Corp....
Items per page:
1 - 3 of 3